HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Animal alternative tests

This article was originally published in The Rose Sheet

Executive Summary

National Toxicology Program is seeking comments and nominations for validation studies of in vitro test methods for identifying endocrine disruptors, agency announces in April 21 Federal Register 1notice. NTP has thus far received two proposals, which were presented by the Interagency Coordinating Committee for the Validation of Alternative Methods at a March meeting of the Scientific Advisory Committee on Alternative Toxicological Methods (2"The Rose Sheet" March 22, 2004, p. 4). ICCVAM will receive comments and nominations and then "develop recommended priorities" for proposed methods, the notice states. In a separate Federal Register 3notice, the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods and ICCVAM report they are seeking nominations for scientific experts to evaluate in vitro test methods for identifying chemicals that potentially cause ocular irritancy...

Related Content

UsernamePublicRestriction

Register

RS012065

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel